These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22897430)

  • 1. Probiotics use to treat irritable bowel syndrome.
    Hosseini A; Nikfar S; Abdollahi M
    Expert Opin Biol Ther; 2012 Oct; 12(10):1323-34. PubMed ID: 22897430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome.
    Barbara G; Zecchi L; Barbaro R; Cremon C; Bellacosa L; Marcellini M; De Giorgio R; Corinaldesi R; Stanghellini V
    J Clin Gastroenterol; 2012 Oct; 46 Suppl():S52-5. PubMed ID: 22955358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: probiotics and prebiotics in irritable bowel syndrome.
    Spiller R
    Aliment Pharmacol Ther; 2008 Aug; 28(4):385-96. PubMed ID: 18532993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rationale and clinical effectiveness of probiotics in irritable bowel syndrome.
    Ringel Y; Ringel-Kulka T
    J Clin Gastroenterol; 2011 Nov; 45 Suppl():S145-8. PubMed ID: 21992954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probiotics and irritable bowel syndrome: rationale, mechanisms, and efficacy.
    Camilleri M
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 1():S123-5. PubMed ID: 18806702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use.
    Barbara G; Stanghellini V; Cremon C; De Giorgio R; Gargano L; Cogliandro R; Pallotti F; Corinaldesi R
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 2():S214-7. PubMed ID: 18685517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Ki Cha B; Mun Jung S; Hwan Choi C; Song ID; Woong Lee H; Joon Kim H; Hyuk J; Kyung Chang S; Kim K; Chung WS; Seo JG
    J Clin Gastroenterol; 2012 Mar; 46(3):220-7. PubMed ID: 22157240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating irritable bowel syndrome with probiotics: the evidence.
    Parkes GC; Sanderson JD; Whelan K
    Proc Nutr Soc; 2010 May; 69(2):187-94. PubMed ID: 20236566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome.
    Brenner DM; Chey WD
    Rev Gastroenterol Disord; 2009; 9(1):7-15. PubMed ID: 19367213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: probiotics for the treatment of irritable bowel syndrome--focus on lactic acid bacteria.
    Clarke G; Cryan JF; Dinan TG; Quigley EM
    Aliment Pharmacol Ther; 2012 Feb; 35(4):403-13. PubMed ID: 22225517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study.
    Guglielmetti S; Mora D; Gschwender M; Popp K
    Aliment Pharmacol Ther; 2011 May; 33(10):1123-32. PubMed ID: 21418261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment.
    Parkes GC; Brostoff J; Whelan K; Sanderson JD
    Am J Gastroenterol; 2008 Jun; 103(6):1557-67. PubMed ID: 18513268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome.
    Zeng J; Li YQ; Zuo XL; Zhen YB; Yang J; Liu CH
    Aliment Pharmacol Ther; 2008 Oct; 28(8):994-1002. PubMed ID: 18671775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options.
    Konturek PC; Brzozowski T; Konturek SJ
    J Physiol Pharmacol; 2011 Dec; 62(6):591-9. PubMed ID: 22314561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last?
    Bixquert Jiménez M
    Rev Esp Enferm Dig; 2009 Aug; 101(8):553-64. PubMed ID: 19785495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of probiotics in the treatment of irritable bowel syndrome.
    Wilhelm SM; Brubaker CM; Varcak EA; Kale-Pradhan PB
    Pharmacotherapy; 2008 Apr; 28(4):496-505. PubMed ID: 18363533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probiotics in functional gastrointestinal disorders: what are the facts?
    Quigley EM
    Curr Opin Pharmacol; 2008 Dec; 8(6):704-8. PubMed ID: 18775516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease.
    Whelan K; Quigley EM
    Curr Opin Gastroenterol; 2013 Mar; 29(2):184-9. PubMed ID: 23286925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probiotics in Irritable Bowel Syndrome: The Science and the Evidence.
    Quigley EM
    J Clin Gastroenterol; 2015; 49 Suppl 1():S60-4. PubMed ID: 26447967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Almost all irritable bowel syndromes are post-infectious and respond to probiotics: consensus issues.
    Cuomo R; Savarese MF; Gargano R
    Dig Dis; 2007; 25(3):241-4. PubMed ID: 17827948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.